Pipeline


Building a biosimilar product portfolio for the long term

Formycon covers the entire range of biosimilar medicines development, from technical-pharmaceutical development to clinical trials, all the way through to preparation and submission of dossiers for regulatory approval by international authorities.

RANIBIZUMABReference product: Lucentis®¹

Details

USTEKINUMABReference product: Stelara®²

Details

AFLIBERCEPTReference product: Eylea®³

Details

notpublished


The company currently has several biosimilar product candidates in advanced development – FYB201, FYB202, FYB203 and FYB206 – with each of these positioned to potentially compete against existing blockbuster biopharmaceuticals, each with sales in the billions of dollars. The market potential for our product candidates is thus substantial.

Formycon holds 50% of the rights in FYB201, a biosimilar candidate for Lucentis®. Formycon holds 100% of the rights in FYB202, a biosimilar candidate for Stelara® and in FYB206, an as yet unpublished biosimilar candidate. FYB203, a biosimilar candidate for Eylea® is in a licensing partnership with Klinge Biopharma GmbH, a Santo Holding (Deutschland) GmbH company.

Formycon regularly publishes updated information regarding the advances in its biosimilar development pipeline, which is expected to be further expanded in the coming years.


¹ Lucentis® is a registered trademark of Genentech, Inc.
² Stelara® is a registered trademark of Johnson & Johnson
³ Eylea® is a registered trademark of Regeneron Pharmaceuticals, Inc.